PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1997; 76(7): 968–974.
PMCID: PMC2228256

Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study.

Abstract

To assess whether there is an additive effect between chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection on the development of hepatocellular carcinoma (HCC), 400 consecutive cirrhotic patients were followed prospectively with periodic abdominal ultrasound examination and measurement of serum alpha-fetoprotein (AFP) level every 4 months. During a follow-up of 1185 person-years, 80 (20%) patients developed HCC, with an annual incidence of 6.8%. The annual incidence was 2.0% in patients negative for hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti-HCV), 6.6% in patients with HBsAg alone, 7.0% in patients with anti-HCV alone and 13.3% in patients co-infected with HBV and HCV. There was a positive linear trend in the annual incidence of HCC among patients without either marker, patients with single viral infection and patients with dual viral infection (P[for trend] < 0.0001). Cox's proportional hazard model indicated that HCV/HBV co-infection [hazard ratio (HR), 6.41; 95% confidence interval (CI), 1.80-22.80], anti-HCV alone (HR, 3.74; 95% CI, 1.07-13.07) and HBsAg alone (HR, 4.06; 95% CI, 1.23-13.34) were independently risk factors of HCC. In conclusion, there is an additive and independent effect modification of HCV and HBV infection on HCC development.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alberti A, Pontisso P, Chemello L, Fattovich G, Benvegnù L, Belussi F, De Mitri MS. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22(1 Suppl):38–41. [PubMed]
  • Benvegnù L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, Alberti A. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994 Nov 1;74(9):2442–2448. [PubMed]
  • Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol. 1993 Sep-Oct;8(5):470–475. [PubMed]
  • Collazos J, Genolla J, Ruibal A. Preliminary study of alpha-fetoprotein in nonmalignant liver diseases. A clinico-biochemical evaluation. Int J Biol Markers. 1992 Apr-Jun;7(2):97–102. [PubMed]
  • Curley SA, Izzo F, Gallipoli A, de Bellis M, Cremona F, Parisi V. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg. 1995 Sep;222(3):375–383. [PubMed]
  • Diamantis ID, McGandy CE, Chen TJ, Liaw YF, Gudat F, Bianchi L. Detection of hepatitis B and C viruses in liver tissue with hepatocellular carcinoma. J Hepatol. 1994 Mar;20(3):405–409. [PubMed]
  • Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993 Jul;18(1):47–53. [PubMed]
  • Jeng JE, Tsai JF. Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol. 1991 May;34(1):74–77. [PubMed]
  • Kaklamani E, Trichopoulos D, Tzonou A, Zavitsanos X, Koumantaki Y, Hatzakis A, Hsieh CC, Hatziyannis S. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA. 1991 Apr 17;265(15):1974–1976. [PubMed]
  • Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990 Oct;12(4 Pt 1):671–675. [PubMed]
  • Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, Bréchot C. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993 Jan;17(1):20–29. [PubMed]
  • Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. [PMC free article] [PubMed]
  • Popper H. Viral versus chemical hepatocarcinogenesis. J Hepatol. 1988 Apr;6(2):229–238. [PubMed]
  • Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646–649. [PubMed]
  • Simonetti RG, Cammà C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991 Jul;36(7):962–972. [PubMed]
  • Simonetti RG, Cammà C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxì A, Ciccaglione A, Giuseppetti R, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med. 1992 Jan 15;116(2):97–102. [PubMed]
  • Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995 Mar;21(3):650–655. [PubMed]
  • Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995 Jun 1;332(22):1463–1466. [PubMed]
  • Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, Tsai JH. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol. 1993 Dec;41(4):296–300. [PubMed]
  • Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver. 1994 Apr;14(2):98–102. [PubMed]
  • Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer. 1994 Jun;69(6):1157–1159. [PMC free article] [PubMed]
  • Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Effects of hepatitis C and B viruses infection on the development of hepatocellular carcinoma. J Med Virol. 1994 Sep;44(1):92–95. [PubMed]
  • Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Increased IgM-containing circulating immune complexes in patients co-infected with hepatitis C and hepatitis B. Medicine (Baltimore) 1995 May;74(3):136–143. [PubMed]
  • Tsai JF, Margolis HS, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. Clin Immunol Immunopathol. 1995 Apr;75(1):39–44. [PubMed]
  • Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer. 1996 Jun;73(12):1498–1502. [PMC free article] [PubMed]
  • Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis. J Hepatol. 1996 Mar;24(3):271–276. [PubMed]
  • Tsai JF, Jeng JE, Ho MS, Wang CS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Serum alanine aminotransferase level in relation to hepatitis B and C virus infections among blood donors. Liver. 1997 Feb;17(1):24–29. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK